An engaging roundtable discussion on the current treatment landscape for acute myeloid leukemia (AML) is led by Amer M. Zeidan, MBBS, of Yale School of Medicine. This expert panel shares insights into the latest advancements, clinical challenges, and innovative therapies transforming AML care. The discussion covers topics such as personalized treatment approaches, novel therapies, and strategies to improve patient outcomes.
Tailoring AML Treatment With Currently Available Agents
By Amer Zeidan, MBBS, MHS, Harry Erba, MD, Courtney DiNardo, MD, MSCE, Maximilian Stahl, MD - Last Updated: December 31, 2024Post Tags:ASH 2024: AML
Related Posts
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Immunotherapy is transforming lymphoma treatment, reducing chemo reliance, and improving long-term outcomes.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.